Published in PLoS One on February 24, 2017
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol (2007) 6.11
Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol (2010) 5.44
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene (2007) 4.27
Triple-negative breast cancer: an unmet medical need. Oncologist (2011) 3.46
TP53 and breast cancer. Hum Mutat (2003) 2.75
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer (1999) 2.36
Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat (2011) 1.96
Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science (2014) 1.74
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res (2011) 1.69
Directed therapy of subtypes of triple-negative breast cancer. Oncologist (2011) 1.23
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res (2012) 1.13
Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer (2012) 1.04
p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. Jpn J Clin Oncol (2011) 1.03
Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat (2015) 0.94
p53 in the DNA-Damage-Repair Process. Cold Spring Harb Perspect Med (2016) 0.86
Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates. Virchows Arch (2010) 0.84
Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study. PLoS One (2015) 0.83
Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget (2016) 0.81
Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget (2016) 0.81
Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. Eur J Cancer (2011) 0.80
Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer. Cancer Res Treat (2016) 0.79
Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival. PLoS One (2015) 0.78
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer. Ann Surg Oncol (2016) 0.78
Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer. Oncotarget (2016) 0.77
A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients. Biomark Med (2016) 0.77
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy. BMC Cancer (2016) 0.77
Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res (2016) 0.77
Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study. BMC Cancer (2016) 0.76
Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series. PLoS One (2016) 0.76
New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer. Tumour Biol (2016) 0.76
Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer. Cancer Res Treat (2016) 0.76
Prognosis of subtypes of the mucinous breast carcinoma in Chinese women: a population-based study of 32-year experience (1983-2014). Oncotarget (2016) 0.76